Who are RYSTIGGO's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vyvgart, Blenrep, ROZANOLIXIZUMAB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rozanolixizumab-noli.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

RYSTIGGO — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RYSTIGGO (ROZANOLIXIZUMAB-NOLI) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neonatal Fc Receptor Blocker [EPC]. Area: Other.

marketed Neonatal Fc Receptor Blocker [EPC] IgG receptor FcRn large subunit p51 Other Live · refreshed every 30 min

Target snapshot

RYSTIGGO (ROZANOLIXIZUMAB-NOLI) — UCB INC.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RYSTIGGO TARGET	ROZANOLIXIZUMAB-NOLI	UCB INC	marketed	Neonatal Fc Receptor Blocker [EPC]	IgG receptor FcRn large subunit p51
Vyvgart	EFGARTIGIMOD ALFA	Argenx Bv	marketed	Endoglycosidase [EPC]	IgG receptor FcRn large subunit p51	2021-01-01
Blenrep	Blenrep	Duke University	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, IgG receptor FcRn large subunit p51
ROZANOLIXIZUMAB	ROZANOLIXIZUMAB		marketed	Neonatal Fc Receptor Blocker [EPC]		2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neonatal Fc Receptor Blocker [EPC] class)

· 1 drug in this class
UCB INC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RYSTIGGO — Competitive Intelligence Brief. https://druglandscape.com/ci/rozanolixizumab-noli. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing